Selected project at the 2020 Paris Peace Forum. The cross-border scientific collaboration framework facilitating the clinical development of COVID-19 therapeutics was presented.

Awarded "la Caixa" Health Research 2020 program funding to tackle leishmaniasis and Chagas disease in collaboration with Fundación MEDINA and DNDi

Initiation in Senegal of the 1st global clinical trials of the COVID-19 drug candidate, nafamostat, in collaboration with Institut Pasteur de Dakar

Reported potent antiviral efficacy of nafamostat against SARS-CoV-2 (J Med Virol. 2021; 93(3): 1403–1408)

Identification of COVID-19 Drug Candidate through Drug Repositioning (Antimicrob Agents Chemother. 2020; 64(7):e00819-20)

Development and technology transfer of innovative anticancer drug candidate reducing the risk of liver cancer recurrence

Co-development and technology transfer of a first-in-class drug candidate effective against methicillin-resistant Staphylococcus aureus (MRSA)

Development of a novel hepatitis B virus cell culture platform mimicking the entire viral life cycle and susceptible to patient-derived virus isolates (J. Hepatol. 2019; 71(2):289–300)

MOU agreement with the Institut Pasteur, and the Institut Pasteur International Network Association to facilitate Korea’s access to Institut Pasteur International Network’s biobank

MOU agreement with Hong Kong University-Pasteur Research Pole for collaboration on influenza research

Awarded the Bio Core Facility Project Supported by Ministry of Science and ICT

Awarded DNDi ’s Project of the Year (by DNDi)

Inauguration of Dr. Wang-Shick Ryu as Chief Executive Officer of IPK

Awarded DNDi ’s Project of the Year (by DNDi)

Qurient Co., Ltd. went public on Korea Securities Dealers Automated Quotation (KOSDAQ)

Q203, a first-in-class (in Korea) tuberculosis drug candidate, designated as an Orphan Drug (development fast track) by US FDA (approved for FDA clinical trial phase I in July 2015)

 Awarded Ministry of Science, ICT, and Future Planning (MSIP)’s 100 Best National R&D project (Q203)

Designated as a University of Science and Technology (UST) member campus

Inauguration of Dr. Hakim Djaballah as Chief Executive Officer of IPK

Awarded for Outstanding Biosafety Management by the Ministry of Health and Welfare

Ranked top in Lab Biosafety Know-How by Korea’s Ministry of Science, ICT, and Future Planning (MSIP)

Discovered Q203, a first-in-class (in Korea) tuberculosis drug candidate that is highly effective against both multi-drug-resistant (MDR) and extensively drug-resistant Mycobacterium tuberculosis. (Pethe, K., Bifani, P., Jang, J. et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19, 1157-1160 (2013))

Awarded the Partnership of the Year by DNDi

IPK’s facility recognized with Outstanding Architecture and Design Silver Award from Gyeonggi Province

Licensed out TB compound, Q203, to Qurient Co., Ltd.

Ranked top in Lab Safety by Korea’s Ministry of Education and Science Technology (MEST)

Relocated to Pangyo Techno Valley campus

Established Qurient Co. Ltd., a spin-off biotech company of IPK

The 1st Bio Safety Level 3 facility certified by the Korean Government (Certification issued by KDCA)

Foundation of IPK (Opened on Korea Institute of Science and Technology (KIST) campus in Seoul)

Appointed Dr. Ulf Nehrbass as the 1st Chief Executive Officer of IPK

Institut Pasteur and Korea Institute of Science and Technology (KIST) agreed to establish IPK with the support of Korea’s Ministry of Science & Technology (Current: Ministry of Science and ICT)